Vidofludimus Calcium for COVID-19: real-time analysis

Download Image

Post

c19early.org

Vidofludimus Calcium for COVID-19

1 study with 220 patients

Serious outcome risk

Vidofludimus Calcium

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Vidofludimus Calcium studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)0%

Mortality (1)0%

RCTs (1)0%

Late (1)0%

00.511.5+

← Vidofludimus
Calcium
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Oct 15 2022	Vehreschild et al., Infectious Diseases and Therapy, doi:10.1007/s40121-022-00690-0	Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Oct 15 2022	no change in mortality (p=1), no change in ventilation (p=1), and no change in progression (p=1). RCT 223 hospitalized COVID-19 patients showing no significant difference in mortality, ventilation, or progression with vidofludimus calcium (a DHODH inhibitor) versus placebo.